National Bank Of Canada Aveo Pharmaceuticals, Inc. Transaction History

National Bank Of Canada

  • $72.7 Billion
  • Q3 2024

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Jan 24, 2022
BUY
$4.69 - $7.4 $469 - $740
100 New
100 $0

Others Institutions Holding AVEO

# of Institutions
1
Shares Held
0
Call Options Held
0
Put Options Held
0
View Full List

About AVEO PHARMACEUTICALS, INC.

AVEO Quotes by TradingView
  • Ticker AVEO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 34,676,000
  • Description
  • AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the ...
More about AVEO
Track This Portfolio

Track National Bank Of Canada Portfolio

Follow National Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of National Bank Of Canada , based on Form 13F filings with the SEC.

News

Stay updated on National Bank Of Canada with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email